Biogen Idec will communicate with doctors once a month on the occurrence of new cases of a rare brain infection in patients using its multiple sclerosis treatment Tysabri, as the biotech firm strives to find the right balance in keeping the medical and financial communities updated on that number. Report [1]
Links:
[1] http://online.wsj.com/article/SB10001424052748703415804575023493628662602.html